Response to esketamine (Spravato) is brisk and bold, but how do you keep patients well over the long term? We look at new research on continuation, tapering, and switching strategies.

Esketamine outperforms quetiapine in TRD remission rates, but the clinical significance of this difference remains uncertain.

Ketamine and esketamine represent some of the most powerful rapid-acting agents in our armamentarium of treatments for depression. However, ketamine is also an addictive substance, and there is emerging evidence that the widespread use of ketamine may be causing more patient harms than we were previously aware of. Here, Dr. Trujillo discusses how to use ketamine safely in clinical practice.

Find out where standard therapies like cariprazine and esketamine have failed in recent trials, along with novel medications like minocycline, zuranolone, pimavanserin, and NAC.